Slide 14 of 30
Notes:
El caso estudio de las heparinas incluye referencias bibliográficas acerca de la efectividad, estudios de evaluación económica, consecuencias, uso de recursos y metodología de la evaluación económica.
1. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975-82.
Economic evaluations (e.g.)
5. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995;155:757-64.
26. National Center for Health Statistics. Abridged U.S. Life Tables. Hyattsville, MD: U.S. Department of Health and Human Services; 1994. Available at http://www.cdc.gov/nchswww.
Cost and Resources Use Data (e.g.)
34. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1997.
8. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7.
